References: Systemic lupus erythematosus (SLE) in adults

  • Andreoli L, Bertsias GK, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Annals of the Rheumatic Diseases 2017;76(3):476-85. https://www.ncbi.nlm.nih.gov/pubmed/27457513
  • Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatology 2019;71(9):1400-12. https://www.ncbi.nlm.nih.gov/pubmed/31385462
  • Australian Rheumatology Association. Prescriber's information on medications for rheumatic diseases in pregnancy. Sydney: Australian Rheumatology Association; 2022. Updated September 2022. https://rheumatology.org.au/For-Healthcare-Professionals/Clinical-Resources/Pregnancy-Prescribing-Info
  • Australian Rheumatology Association (ARA). Prescriber’s Information on Medications for Autoimmune and Inflammatory Rheumatic Diseases (AIIRD) in Pregnancy. ARA; 2011. Updated September 2022. Accessed March 2023. https://rheumatology.org.au/For-Healthcare-Professionals/Clinical-Resources/Pregnancy-Prescribing-Info
  • Barber MRW, Drenkard C, Falasinnu T, Hoi A, Mak A, Kow NY, et al. Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol 2021;17(9):515-32. https://www.ncbi.nlm.nih.gov/pubmed/34345022
  • Basta F, Fasola F, Triantafyllias K, Schwarting A. Systemic Lupus Erythematosus (SLE) Therapy: The Old and the New. Rheumatol Ther 2020;7(3):433-46. https://www.ncbi.nlm.nih.gov/pubmed/32488652
  • Bultink IEM, de Vries F, van Vollenhoven RF, Lalmohamed A. Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls. Rheumatology (Oxford) 2021;60(1):207-16. https://www.ncbi.nlm.nih.gov/pubmed/32653901
  • Drosos GC, Vedder D, Houben E, Boekel L, Atzeni F, Badreh S, et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Annals of the Rheumatic Diseases 2022;81(6):768-79. https://www.ncbi.nlm.nih.gov/pubmed/35110331
  • Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Annals of the Rheumatic Diseases 2019;78(6):736-45. https://www.ncbi.nlm.nih.gov/pubmed/30926722
  • Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Annals of the Rheumatic Diseases 2020;79(6):713-23. https://www.ncbi.nlm.nih.gov/pubmed/32220834
  • Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update on the diagnosis and management of systemic lupus erythematosus. Annals of the Rheumatic Diseases 2021;80(1):14-25. https://www.ncbi.nlm.nih.gov/pubmed/33051219
  • Hurst C, Soto M, Vina ER, Rodgers KE. Renin-Angiotensin System-Modifying Antihypertensive Drugs Can Reduce the Risk of Cardiovascular Complications in Lupus: A Retrospective Cohort Study. Am J Med 2023;136(3):284-93 e4. https://www.ncbi.nlm.nih.gov/pubmed/36495935
  • Kostopoulou M, Nikolopoulos D, Parodis I, Bertsias G. Cardiovascular Disease in Systemic Lupus Erythematosus: Recent Data on Epidemiology, Risk Factors and Prevention. Curr Vasc Pharmacol 2020;18(6):549-65. https://www.ncbi.nlm.nih.gov/pubmed/31880245
  • Massias JS, Smith EMD, Al-Abadi E, Armon K, Bailey K, Ciurtin C, et al. Clinical and laboratory characteristics in juvenile-onset systemic lupus erythematosus across age groups. Lupus 2020;29(5):474-81. https://www.ncbi.nlm.nih.gov/pubmed/32233733
  • Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA. Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases. Lupus 2009;18(9):767-76. https://www.ncbi.nlm.nih.gov/pubmed/19578100
  • Russell MD, Dey M, Flint J, Davie P, Allen A, Crossley A, et al. British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford) 2022. https://www.ncbi.nlm.nih.gov/pubmed/36318966
  • Schwartz N, Stock AD, Putterman C. Neuropsychiatric lupus: new mechanistic insights and future treatment directions. Nat Rev Rheumatol 2019;15(3):137-52. https://www.ncbi.nlm.nih.gov/pubmed/30659245
  • Shaban A, Leira EC. Neurological Complications in Patients with Systemic Lupus Erythematosus. Curr Neurol Neurosci Rep 2019;19(12):97. https://www.ncbi.nlm.nih.gov/pubmed/31773306
  • Singh JA, Shah NP, Mudano AS. Belimumab for systemic lupus erythematosus. Cochrane Database of Systematic Review 2021;2(2):CD010668. https://www.ncbi.nlm.nih.gov/pubmed/33631841
  • Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Annals of the Rheumatic Diseases 2019;78(10):1296-304. https://www.ncbi.nlm.nih.gov/pubmed/31092409
  • The Faculty of Sexual & Reproductive Healthcare (FSRH). UK Medical Eligibility Criteria for Contraceptive Use (UKMEC). UK: The Faculty of Sexual & Reproductive Healthcare (FSRH),; 2016. Updated September 2019. Accessed August 2022. https://www.fsrh.org/standards-and-guidance/uk-medical-eligibility-criteria-for-contraceptive-use-ukmec/